Type 2 diabetes (T2D) is a metabolic disease, primarily characterized by the beta cells’ dysfunction and the lack of their ability to produce insulin.
It is important not only to treat T2D patients but also to predict insulin resistance development to manage the patients and come up with better treatment strategies. In the recent publication the authors studied the plethora of biomarkers that would allow predicting the gradual development of insulin resistance in patients with T2D.
Several metabolic and lipid markers were suggested to predict a faster progression towards insulin requirement, among which were eight different species of triglycerides and the level of the lipid species sphingomyelin 42:2;2.
Find more information here:
#Type2Diabetes #lipidomics #LipidMetabolism #lipid #MassSpectrometry
